patent.fyi
Applications  /  US 2026/0356878
United States Patent Application Publication

US 2026/0356878 A1

Published
Nov 12, 2026
Filed
Apr 10, 2026
Earliest date on the face
Oct 19, 2020
Classification
C07J 5/0053
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Inclusion in cyclodextrin cavities

What ifWhat if cyclodextrin cavities carry the steroid as a host–guest complex?
Claim language“A solvate”

Mix the steroid with aqueous hydroxypropyl beta-cyclodextrin, then freeze-dry the mixture to recover a powder. The hydrophobic cavity accommodates part of the steroid, and the hydrophilic exterior supports redispersion in water.

1.1Adsorption inside silica pores

What ifWhat if mesoporous silica carries the steroid on its internal surfaces?
Claim language“A solvate”

Load a steroid solution into mesoporous silica by capillary infiltration and evaporate the carrier solvent under reduced pressure. The pore surfaces retain the deposited steroid and provide a high contact area for release into a liquid vehicle.

1.1Steroid in lipid particles

What ifWhat if solid lipid particles carry the steroid within a glyceride matrix?
Claim language“A solvate”

Dissolve the steroid in molten glyceryl behenate and disperse the melt in a warm aqueous surfactant solution by high-pressure homogenization. Cool the dispersion to solidify the droplets and retain the steroid within the lipid particles.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Component substitution

Deuterated dimethyl sulfoxide as lattice solvent

Dimethyl sulfoxide-d₆ replaces ordinary dimethyl sulfoxide as the lattice solvent. A capped crystallization vial holds clascoterone dissolved in the deuterated solvent, and slow cooling generates a slurry for filtration. Powder X-ray diffraction checks the crystal phase, and deuterium nuclear magnetic resonance of dissolved crystals confirms the presence of the substituted solvent.

Parameter or scale variation

Parallel crystallization at microliter scale

A sealed 24-well glass plate holds 200 microliters of a saturated clascoterone solution in dimethyl sulfoxide per well at 40 °C. The plate cools to 25 °C at 0.2 °C per minute and remains at 25 °C for 16 hours. The recovered solids undergo powder X-ray diffraction, and thermogravimetry coupled with mass spectrometry measures solvent release from samples with matching diffraction patterns.

Combination with existing systems

Solvate recovery in a filter dryer

A jacketed crystallizer transfers the clascoterone–dimethyl sulfoxide slurry into an agitated filter dryer fitted with a porous filter plate and a nitrogen inlet. Nitrogen pressure displaces the mother liquor through the plate, and the agitator loosens the drained cake before discharge. Powder X-ray diffraction and thermogravimetry of a cake sample verify the crystal phase and retained solvent content before discharge.

Solvate testing in a humidity chamber

A programmable humidity chamber holds open shallow dishes containing thin layers of the clascoterone–dimethyl sulfoxide solvate. The chamber maintains a fixed temperature while stepping through set relative humidity values, and replicate dishes provide separate samples for each exposure interval. Powder X-ray diffraction tracks phase changes, and thermogravimetry coupled with mass spectrometry distinguishes water uptake from dimethyl sulfoxide loss.

Automated or data-driven variant

Raman monitoring of seeded crystallization

A stirred, jacketed vessel holds a supersaturated solution of clascoterone in dimethyl sulfoxide and receives seeds of the target solvate. An immersion Raman probe collects spectra that software compares with reference spectra from the starting solution and the isolated solvate. A controller tracks the solvate signal and initiates filtration when the signal reaches a preset level and stabilizes.

Specific version of a part

Controlled antisolvent crystallization

Meter ethyl acetate into a stirred solution of the steroid in dimethyl sulfoxide containing solvate seeds. Control the feed rate to limit local supersaturation, and verify the recovered phase by powder X-ray diffraction and quantitative proton nuclear magnetic resonance.

Vapor diffusion crystal growth

Place an open vial of concentrated steroid solution in dimethyl sulfoxide inside a sealed chamber containing a separate ethyl acetate reservoir. Ethyl acetate vapor enters the solution gradually and lowers steroid solubility as crystals grow, and single-crystal X-ray diffraction locates dimethyl sulfoxide in the crystal lattice.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2014/0099365 A1
Published
Apr 10, 2014
Filed
Dec 11, 2013
Class
C07D 471/04
Document BUS 9,181,243 B2
Published
Nov 10, 2015
Filed
Jun 30, 2014
Class
C07D 471/04
Claim 1
Document A
Document B
1.1A solvate of Clascoterone with dimethyl sulfoxide.
The present invention relates to solid oral pharmaceutical dosage forms, suitably tablets, suitably capsules, comprising N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, represented by the following formula (I) and hereinafter referred to as Compound A:
A · US 2014/0099365 A1 · ¶ 2
The crystalline form M of trametinib dimethyl sulfoxide solvate (hereinafter named “Form M” for convenience), is a solvated form of trametinib at 1:1 molar ratio of trametinib to dimethyl sulfoxide, and has a formula as the following:
B · US 9,181,243 B2 · ¶ 10

An empty cell means only that no passage was reproduced there.

Statements in these documents
It would be desirable to provide Compound A in a solid oral pharmaceutical dosage form on a commercial scale with a desirable pharmacodynamic profile.
A · US 2014/0099365 A1 · ¶ 7
The invention also relates to a process for making solid oral pharmaceutical dosage forms, suitably tablets, suitably capsules, comprising Compound A.
A · US 2014/0099365 A1 · ¶ 8
Phase III clinical trials show that the therapeutic effect of trametinib is significantly better than traditional chemotherapy drugs for treatment of advanced melanoma with BRAF V600E/K mutations and for treatment of BRAF V600E or V600K mutation-positive metastatic cutaneous melanoma.
B · US 9,181,243 B2 · ¶ 5
However, the trametinib dimethyl sulfoxide solvate obtained by the conventional methods is not stable and is easy to transform its crystalline form.
B · US 9,181,243 B2 · ¶ 7
Cite aspatent.fyi, US 2026/0356878 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356878/, SHA-256 d4fc68485e846b2f3f13d44be084f9e9cbdc9d040dc57eef7dfddaa14517bdf7
First published
Permanent addresshttps://patent.fyi/US20260356878/
Content fingerprint (SHA-256)d4fc68485e846b2f3f13d44be084f9e9cbdc9d040dc57eef7dfddaa14517bdf7
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi